S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?

10 Best Penny Stocks to Buy Now

Let's talk penny stocks. We've all played with them at one time or another, buying shares of a company trading at $1.00 or less because the stock was cheap.

Maybe you read online that a penny stock's price was likely to skyrocket because some big piece of news is going to be announced soon. Maybe your golfing buddy told you to checkout a penny stock and get in before it's too late.

Sometimes penny stock trades work out great and you can book a quick win, but often times the share price stays flat (or even goes down) and the whole trade was a giant waste of time and money.

Trading penny stocks can often feel like gambling, because you're putting up a small amount of money hoping for a big win. You can also lose all your money when you make the wrong bet.

But what if you could take the guess work out of trading penny stocks? Well, there might be a way to do that. We've gathered analyst research reports from every Wall Street firm on every public company whose shares are trading for under $1.00. There are literally thousands of these reports.

Our team sifted through them and found the ten penny stocks that Wall Street's top analysts are nearly universally bullish about. They believe these companies will have incredible upside in the next twelve months.

#1 - Continental Resources (NYSE:CLR)

Upgrades from Top-Ranked Analysts
15 (in the last 90 days)
Consensus Rating
Hold
Rating Score
2.1
Ratings Breakdown
3 Buy Ratings, 9 Hold Ratings, 2 Sell Ratings.
Consensus Price Target
$72.82

Continental Resources logoContinental Resources, Inc is an independent oil producer engaged in the exploration, development, and production of crude oil and natural gas. The firm's operations include horizontal drilling and protecting groundwater. The company was founded by Harold G. Hamm in 1967 and is headquartered in Oklahoma City, OK.
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/24/2022MizuhoBoost Price TargetNeutral$72.00 ➝ $74.00
10/24/2022Raymond JamesDowngradeOutperform ➝ Market Perform$74.00
10/19/2022Morgan StanleyUpgradeUnderweight ➝ Equal Weight$67.00 ➝ $74.00
10/18/2022Piper SandlerBoost Price TargetUnderweight$70.00 ➝ $74.00
8/31/2022BarclaysLower Price TargetUnderweight$73.00 ➝ $70.00
8/2/2022Piper SandlerDowngradeNeutral ➝ Sell$76.00 ➝ $70.00
8/1/2022ScotiabankDowngradeSector Outperform ➝ Sector Perform
7/29/2022BarclaysLower Price Target$77.00 ➝ $73.00
7/22/2022Piper SandlerDowngradeNeutral ➝ Underweight$76.00 ➝ $70.00
7/19/2022CowenSet Price Target$70.00

#2 - Banco de Sabadell (OTCMKTS:BNDSF)

Upgrades from Top-Ranked Analysts
8 (in the last 90 days)
Consensus Rating
Hold
Rating Score
2.4
Ratings Breakdown
4 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings.
Consensus Price Target
$0.92 (2.1% Upside)

Banco de Sabadell logoBanco de Sabadell, SA provides banking products and services to personal, business, and private customers in Spain and internationally. The company offers retail banking products, such as current and savings accounts, personal loans, cards, and mortgages. It also provides financial products and services to large and medium enterprises, SMEs, shops and self-employed workers, private individuals, and professionals; and consumer finance, asset management, and bancassurance services. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/23/2022Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight€1.00 ➝ €1.10
10/28/2022Societe GeneraleBoost Price Target€0.85
10/18/2022Deutsche Bank AktiengesellschaftBoost Price Target€1.00 ➝ €1.05
9/7/2022JPMorgan Chase & Co.Boost Price Target€0.90 ➝ €0.95
7/29/2022Oddo BhfUpgradeUnderperform ➝ Neutral
7/12/2022UBS GroupLower Price TargetBuy ➝ Buy€1.15 ➝ €1.05
6/28/2022Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight€1.00 ➝ €1.10
6/17/2022UBS GroupBoost Price TargetBuy ➝ Buy€1.10 ➝ €1.15
5/27/2022UBS GroupLower Price TargetBuy ➝ Buy€1.15 ➝ €1.10
5/6/2022JPMorgan Chase & Co.Boost Price Target€0.90 ➝ €0.95

#3 - Saipem (OTCMKTS:SAPMY)

Upgrades from Top-Ranked Analysts
7 (in the last 90 days)
Consensus Rating
Buy
Rating Score
2.9
Ratings Breakdown
6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$6.19 (1,963.5% Upside)

Saipem logoSaipem SpA provides energy and infrastructure solutions worldwide. The company operates through five divisions: Offshore Engineering & Construction (E&C), Onshore Engineering & Construction, Offshore Drilling, Onshore Drilling, and XSIGHT. It offers engineering, construction, installation of platforms, pipelines, subsea fields, maintenance, modification, operation, and decommissioning activities, as well as develops marine wind farms and energy integration projects. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/23/2022Societe GeneraleUpgradeSell ➝ Buy
11/17/2022Berenberg BankUpgradeHold ➝ Buy
11/9/2022JPMorgan Chase & Co.Initiated CoverageOverweight
11/8/2022HSBCInitiated CoverageBuy
10/20/2022Jefferies Financial GroupUpgradeHold ➝ Buy
8/8/2022Jefferies Financial GroupUpgradeUnderperform ➝ Hold
6/28/2022AlphaValueUpgradeSell ➝ Buy
5/23/2022JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral€5.71 ➝ €6.19
4/22/2022BarclaysBoost Price TargetEqual Weight ➝ Equal Weight€5.71 ➝ €6.19
10/29/2021JPMorgan Chase & Co.Reiterated RatingNeutral

#4 - Core Scientific (NASDAQ:CORZ)

Upgrades from Top-Ranked Analysts
6 (in the last 90 days)
Consensus Rating
Hold
Rating Score
2.3
Ratings Breakdown
3 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
6.28 (4,607.4% Upside)

Core Scientific logoCore Scientific, Inc operates facilities for digital asset mining and colocation services in North America. It provides blockchain infrastructure, software solutions, and services. The company mines digital assets for its own account and provides hosting colocation services for other large-scale miners. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/3/2022DA DavidsonDowngradeBuy ➝ Neutral
11/1/2022Compass PointDowngradeBuy ➝ Neutral
10/28/2022B. RileyDowngradeBuy ➝ Neutral
10/28/2022HC WainwrightDowngradeBuy ➝ Neutral
10/28/2022BarclaysDowngradeOverweight ➝ Equal Weight
10/28/2022Chardan CapitalDowngradeBuy ➝ Neutral
10/27/2022BTIG ResearchDowngradeBuy ➝ Neutral
10/25/2022Compass PointLower Price TargetBuy$4.00 ➝ $2.25
10/24/2022DA DavidsonInitiated CoverageBuy ➝ Neutral
10/7/2022B. RileyLower Price TargetBuy$7.00 ➝ $5.00

#5 - Petrofac (OTCMKTS:POFCY)

Upgrades from Top-Ranked Analysts
5 (in the last 90 days)
Consensus Rating
Buy
Rating Score
2.8
Ratings Breakdown
5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$150.00 (29,960.1% Upside)

Petrofac logoPetrofac Limited designs, builds, manages, and maintains infrastructure for the energy industries in the United Kingdom, Algeria, Thailand, Oman, Kuwait, Iraq, the United Arab Emirates, the Netherlands, and internationally. It operates through three segments: Engineering & Construction (E&C); Asset Solutions; and Integrated Energy Services (IES). Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/21/2022JPMorgan Chase & Co.Lower Price TargetGBX 175 ➝ GBX 170
10/14/2022Peel HuntUpgradeHold ➝ Buy
8/24/2022CheuvreuxDowngradeBuy ➝ HoldGBX 140
5/23/2022JPMorgan Chase & Co.Boost Price TargetGBX 170 ➝ GBX 180
5/5/2022The Goldman Sachs GroupInitiated CoverageBuy
5/3/2022Berenberg BankUpgradeHold ➝ Buy
4/14/2022JPMorgan Chase & Co.Boost Price TargetGBX 160 ➝ GBX 170
4/8/2022Exane BNP ParibasUpgradeNeutral ➝ OutperformGBX 140
12/10/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
11/9/2021Jefferies Financial GroupUpgradeHold ➝ Buy

#6 - CECO Environmental (NASDAQ:CECE)

Upgrades from Top-Ranked Analysts
4 (in the last 90 days)
Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$14.25

CECO Environmental logoCECO Environmental Corp. provides industrial air quality and fluid handling systems worldwide. It operates in two segments: Engineered Systems Segment and Industrial Process Solutions Segment. The company engineers, designs, builds, and installs systems that capture, clean, and destroy air- and water-borne emissions from industrial facilities as well as fluid handling, gas separation, and filtration systems. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/24/2022Craig HallumInitiated CoverageBuy$17.00
8/9/2022Needham & Company LLCBoost Price TargetBuy$9.00 ➝ $11.00
7/1/2022Needham & Company LLCReiterated RatingBuy$9.00
4/29/2022Lake Street CapitalInitiated CoverageBuy$14.00
3/15/2022HC WainwrightReiterated RatingBuy$15.00
3/15/2022Needham & Company LLCReiterated RatingBuy$9.00
11/9/2021Needham & Company LLCLower Price TargetBuy$10.00 ➝ $9.00
3/4/2021HC WainwrightBoost Price TargetBuy$9.00 ➝ $15.00
11/5/2020Needham & Company LLCLower Price TargetBuy$10.00 ➝ $9.00
8/10/2020Needham & Company LLCReiterated RatingBuy$10.00

#7 - Cingulate (NASDAQ:CING)

Upgrades from Top-Ranked Analysts
4 (in the last 90 days)
Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$8.75 (781.4% Upside)

Cingulate logoCingulate Inc, a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/22/2022Maxim GroupInitiated CoverageBuy
10/3/2022Ascendiant Capital MarketsInitiated CoverageBuy
1/20/2022LaidlawInitiated CoverageBuy$8.50
1/11/2022AegisInitiated CoverageBuy$9.00

#8 - Daré Bioscience (NASDAQ:DARE)

Upgrades from Top-Ranked Analysts
4 (in the last 90 days)
Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$9.00 (911.1% Upside)

Daré Bioscience logoDaré Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/30/2022JonestradingInitiated CoverageBuy
10/18/2022HC WainwrightReiterated RatingBuy$6.00
5/13/2022Maxim GroupInitiated CoverageBuy$4.00
4/1/2022Maxim GroupInitiated CoverageBuy$4.00
4/1/2022Roth CapitalBoost Price Target$11.00 ➝ $17.00
4/1/2022HC WainwrightBoost Price TargetBuy$5.00 ➝ $6.00
1/19/2022Brookline Capital ManagementReiterated RatingBuy
12/8/2021HC WainwrightReiterated RatingBuy$5.00
7/8/2021HC WainwrightReiterated RatingBuy
6/30/2021Roth CapitalBoost Price TargetBuy$9.00 ➝ $11.00

#9 - Satsuma Pharmaceuticals (NASDAQ:STSA)

Upgrades from Top-Ranked Analysts
4 (in the last 90 days)
Consensus Rating
Hold
Rating Score
2.4
Ratings Breakdown
2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$7.40 (712.9% Upside)

Satsuma Pharmaceuticals logoSatsuma Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/17/2022LADENBURG THALM/SH SHLower Price Target$3.00
11/16/2022JonestradingDowngradeBuy ➝ Hold
11/15/2022HC WainwrightLower Price TargetBuy$18.00 ➝ $3.00
11/15/2022MizuhoDowngradeBuy ➝ Neutral$13.00 ➝ $2.00
11/15/2022SVB LeerinkDowngradeOutperform ➝ Market Perform
10/10/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$5.00 ➝ $15.00
9/21/2022HC WainwrightBoost Price TargetBuy$15.00 ➝ $18.00
8/31/2022LADENBURG THALM/SH SHInitiated CoverageBuy$16.00
8/24/2022JonestradingInitiated CoverageBuy$14.00
6/21/2022HC WainwrightReiterated RatingBuy

#10 - HEXO (NYSE:HEXO)

Upgrades from Top-Ranked Analysts
4 (in the last 90 days)
Consensus Rating
Hold
Rating Score
1.9
Ratings Breakdown
1 Buy Ratings, 4 Hold Ratings, 2 Sell Ratings.
Consensus Price Target
$0.72 (328.7% Upside)

HEXO logoHEXO Corp., through its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/16/2022Cantor FitzgeraldReiterated RatingNeutral
6/16/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold
6/15/2022Atb Cap MarketsDowngradeSector Perform ➝ Underperform
6/15/2022Alliance Global PartnersDowngradeBuy ➝ Neutral
3/4/2022Canaccord Genuity GroupUpgradeHold ➝ Buy
3/4/2022Cantor FitzgeraldLower Price TargetNeutral$1.20 ➝ $0.90
3/4/2022Canaccord Genuity GroupUpgradeHold ➝ Speculative Buy
3/3/2022Atb Cap MarketsUpgradeUnderperform ➝ Sector Perform
1/27/2022Jefferies Financial GroupUpgradeUnderperform ➝ Hold$1.07 ➝ $0.53
12/15/2021CIBCDowngradeNeutral ➝ Sector Underperform

 

While no one can say for sure that these will be the ten best penny stocks next year, Wall Street's top analysts are giving them high price targets, "buy" ratings and are telling their clients to acquire shares.

More Investing Slideshows: